Janssen Pharmaceutica Nv
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1953-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
4
Active:3
Completed:1
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
16
PHILIPPINES:11
NMPA:5
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)No trials found
News
Nanobiotix Secures EU Regulatory Harmonization and New Patent for Cancer Radioenhancer JNJ-1900
European health authorities have reclassified JNJ-1900 (NBTXR3) from a medical device to a medicinal product, harmonizing its regulatory status with the US and other major markets.
Contineum Therapeutics On Track for Key Clinical Milestones with PIPE-791 and PIPE-307 Programs
Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.
Nanobiotix's Radioenhancer JNJ-1900 Enters Phase 2 Trial for Unresectable NSCLC
Nanobiotix has dosed the first patient in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3) for Stage 3 unresectable non-small cell lung cancer.